← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Provincial Health Services Authority
Vancouver, BC
$14,193,906
Total funding
14
Grants
Funding over time
peak $3.1M · FY2016–25$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,581,026 · 7
DOD$2,612,880 · 7
By mechanism
U01$4,678,848 · 1
R01$4,362,597 · 3
—$2,612,880 · 7
U24$1,182,160 · 1
R37$1,177,509 · 1
R21$179,912 · 1
Investigators at Provincial Health Services Authority
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Comparative Modeling of Lung Cancer Prevention, Early Detection and Treatment Interventions$1,600,160
U01 · FY2022 · CA
Comparative Modeling of Lung Cancer Prevention, Early Detection and Treatment Interventions$1,554,893
U01 · FY2025 · CA
Comparative Modeling of Lung Cancer Prevention, Early Detection and Treatment Interventions$1,523,795
U01 · FY2023 · CA
MECHANISTIC INVESTIGATION OF BREAST CANCER SYNTHETIC LETHALITY THROUGH INHIBITION OF CDK12$516,109
· FY2016 · Department of the Army
MECHANISTIC INVESTIGATION OF BREAST CANCER SYNTHETIC LETHALITY THROUGH INHIBITION OF CDK12$510,776
· FY2016 · Department of the Army
MECHANISMS AND THERAPEUTIC STRATEGIES FOR OVERCOMING MNA-MEDIATED IMMUNE SUPPRESSION IN OVARIAN CANCER$495,000
· FY2022 · Department of the Army
Structure, function, and application of novel antagonists of the intrinsically disordered androgen receptor amino-terminal domain as imaging agents and therapeutics$445,892
R01 · FY2025 · CA
Structure, function, and application of novel antagonists of the intrinsically disordered androgen receptor amino-terminal domain as imaging agents and therapeutics$442,720
R01 · FY2021 · CA
DECODING AND TARGETING GENOMIC INSTABILITY IN PEDIATRIC OSTEOSARCOMA$438,500
· FY2025 · Defense Health Agency
Structure, function, and application of novel antagonists of the intrinsically disordered androgen receptor amino-terminal domain as imaging agents and therapeutics$436,974
R01 · FY2023 · CA
Structure, function, and application of novel antagonists of the intrinsically disordered androgen receptor amino-terminal domain as imaging agents and therapeutics$433,461
R01 · FY2022 · CA
Structure, function, and application of novel antagonists of the intrinsically disordered androgen receptor amino-terminal domain as imaging agents and therapeutics$423,596
R01 · FY2024 · CA
Integrating investigational miR371a-3p with conventional radiology imaging for earlier and more precise detection of active germ cell malignancy: A BCC/SWOG/S1823 secondary use of data collaboration.$423,319
R37 · FY2022 · CA
Integrative miRNA data analysis for clinical cancer genomics$398,334
U24 · FY2020 · CA
Integrative miRNA data analysis for clinical cancer genomics$397,386
U24 · FY2018 · CA
Integrative miRNA data analysis for clinical cancer genomics$386,440
U24 · FY2019 · CA
Integrating investigational miR371a-3p with conventional radiology imaging for earlier and more precise detection of active germ cell malignancy: A BCC/SWOG/S1823 secondary use of data collaboration.$382,956
R37 · FY2023 · CA
Integrating investigational miR371a-3p with conventional radiology imaging for earlier and more precise detection of active germ cell malignancy: A BCC/SWOG/S1823 secondary use of data collaboration.$371,234
R37 · FY2024 · CA
Delineating the mechanisms of androgen receptor activation function-1 antagonists for development of novel prostate cancer therapeutics$275,849
R01 · FY2021 · CA
Delineating the mechanisms of androgen receptor activation function-1 antagonists for development of novel prostate cancer therapeutics$275,849
R01 · FY2020 · CA